Osteoarthritis is often treated as an inevitable consequence of aging: joints wear down, pain increases, mobility declines, and some patients eventually undergo joint-replacement surgery. But a new initiative from the Advanced Research Projects Agency for Health (ARPA-H) is pursuing a far more ambitious goal—helping damaged joints regenerate living tissue and potentially eliminating osteoarthritis rather than simply managing its symptoms.
ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis, or NITRO, program is developing treatments designed to restore cartilage and bone damaged by osteoarthritis. The agency reports that its research teams have already regenerated both tissues in osteoarthritic animal models and are now completing the studies needed before seeking FDA clearance to begin first-in-human clinical trials, expected next year.
Osteoarthritis affects approximately 32 million Americans annually and costs the U.S. health system more than $132 billion each year, according to ARPA-H. It is also a major cause of disability. Existing care may include physical therapy, pain medicines, injections, weight management, and ultimately joint replacement. While these approaches can improve symptoms and function, they generally do not reverse the underlying loss of cartilage and changes in bone structure that drive the disease.
NITRO takes a regenerative approach across three areas: targeted bone regeneration, targeted cartilage regeneration, and biologically integrated knee replacements made from living human tissue. The program’s objective is to match the intervention to where a patient is in the osteoarthritis journey—from early tissue damage to advanced disease requiring joint replacement.
For people who do not yet need a replacement joint, the program is exploring one-time injectable therapies intended to halt bone or cartilage degeneration and rebuild the joint’s native tissues. At Duke University, researchers have developed time-release drug formulations designed to stimulate regeneration of bone and articular cartilage. The team is also working on an intravenous, time-release formulation for patients with osteoarthritis affecting multiple joints, potentially avoiding repeated injections into separate joints. ARPA-H states that these therapies could require no more than one clinic visit per year.
A University of Colorado Boulder team is developing a separate set of regenerative strategies. One uses injectable particles that deliver intermittent doses of a repurposed regenerative drug over months. Another is aimed at sizable cartilage injuries: an engineered-protein mixture is placed into the joint arthroscopically and cured in position to support focused tissue repair. In animal studies, the university reports that these approaches helped aging or injured joints repair themselves within weeks.
For patients with severe disease, Columbia University is taking on one of the most challenging problems in orthopedics: replacing an artificial knee with a living one. The team has engineered a 3D-printed human knee construct built on a biodegradable scaffold and infused with adult stem cells. The cells may come from a patient’s own abdominal fat tissue or from banked adult inducible pluripotent stem cells. After implantation, the scaffold is intended to gradually disappear while cells regenerate cartilage and bone. The construct is designed to resemble conventional metal-and-plastic joint replacements, which could allow surgeons to use familiar implantation methods.
These technologies are still preclinical, meaning they have not yet been shown to be safe or effective in people. That distinction is essential: successful animal results do not guarantee that a treatment will work in human osteoarthritis. Still, the NITRO program represents a notable shift in ambition—from controlling osteoarthritis symptoms to attempting true tissue restoration.
ARPA-H also says NITRO teams must meet rigorous clinical-trial standards, including enrolling more than 50% women and ensuring participants reflect populations disproportionately affected by osteoarthritis, including American Indian and Alaska Native communities. The program is pairing scientific development with planning for affordability and access, a necessary consideration if regenerative therapies eventually reach the clinic.
If the upcoming human studies support the early findings, NITRO could help redefine what osteoarthritis care looks like: not merely reducing pain in a deteriorating joint, but giving the joint a chance to heal.
